Article ; Online: Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.
Biopharmaceutics & drug disposition
2021 Volume 42, Issue 6, Page(s) 263–284
Abstract: Renal (RIP) and hepatic (HIP) impairments are prevalent conditions in cancer patients. They can cause changes in gastric emptying time, albumin levels, hematocrit, glomerular filtration rate, hepatic functional volume, blood flow rates, and metabolic ... ...
| Abstract | Renal (RIP) and hepatic (HIP) impairments are prevalent conditions in cancer patients. They can cause changes in gastric emptying time, albumin levels, hematocrit, glomerular filtration rate, hepatic functional volume, blood flow rates, and metabolic activity that can modify drug pharmacokinetics. Performing clinical studies in such populations has ethical and practical issues. Using predictive physiologically-based pharmacokinetic (PBPK) models in the evaluation of the PK of alectinib, ruxolitinib, and panobinostat exposures in the presence of cancer, RIP, and HIP can help in using optimal doses with lower toxicity in these populations. Verified PBPK models were customized under scrutiny to account for the pathophysiological changes induced in these diseases. The PBPK model-predicted plasma exposures in patients with different health conditions within average 2-fold error. The PBPK model predicted an area under the curve ratio (AUCR) of 1, and 1.8, for ruxolitinib and panobinostat, respectively, in the presence of severe RIP. On the other hand, the severe HIP was associated with AUCR of 1.4, 2.9, and 1.8 for alectinib, ruxolitinib, and panobinostat, respectively, in agreement with the observed AUCR. Moreover, the PBPK model predicted that alectinib therapeutic cerebrospinal fluid levels are achieved in patients with non-small cell lung cancer, moderate HIP, and severe HIP at 1-, 1.5-, and 1.8-fold that of healthy subjects. The customized PBPK models showed promising ethical alternatives for simulating clinical studies in patients with cancer, RIP, and HIP. More work is needed to quantify other pathophysiological changes induced by simultaneous affliction by cancer and RIP or HIP. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/blood ; Antineoplastic Agents/pharmacokinetics ; Area Under Curve ; Carbazoles/blood ; Carbazoles/pharmacokinetics ; Fasting/metabolism ; Female ; Humans ; Liver Diseases/blood ; Liver Diseases/metabolism ; Male ; Middle Aged ; Models, Biological ; Neoplasms/blood ; Neoplasms/metabolism ; Nitriles/blood ; Nitriles/pharmacokinetics ; Panobinostat/blood ; Panobinostat/pharmacokinetics ; Piperidines/blood ; Piperidines/pharmacokinetics ; Protein Kinase Inhibitors/blood ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrazoles/blood ; Pyrazoles/pharmacokinetics ; Pyrimidines/blood ; Pyrimidines/pharmacokinetics ; Renal Insufficiency/blood ; Renal Insufficiency/metabolism | |||||
| Chemical Substances | Antineoplastic Agents ; Carbazoles ; Nitriles ; Piperidines ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; ruxolitinib (82S8X8XX8H) ; Panobinostat (9647FM7Y3Z) ; alectinib (LIJ4CT1Z3Y) | |||||
| Language | English | |||||
| Publishing date | 2021-05-05 | |||||
| Publishing country | England | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 603014-2 | |||||
| ISSN | 1099-081X ; 0142-2782 | |||||
| ISSN (online) | 1099-081X | |||||
| ISSN | 0142-2782 | |||||
| DOI | 10.1002/bdd.2282 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1520: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.